vs
Side-by-side financial comparison of DIODES INC (DIOD) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $391.6M, roughly 1.6× DIODES INC). DIODES INC runs the higher net margin — 2.6% vs -14.8%, a 17.4% gap on every dollar of revenue. On growth, DIODES INC posted the faster year-over-year revenue change (15.4% vs -10.5%). Over the past eight quarters, DIODES INC's revenue compounded faster (13.9% CAGR vs -6.6%).
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
DIOD vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $391.6M | $619.8M |
| Net Profit | $10.2M | $-91.8M |
| Gross Margin | 31.1% | — |
| Operating Margin | 3.4% | — |
| Net Margin | 2.6% | -14.8% |
| Revenue YoY | 15.4% | -10.5% |
| Net Profit YoY | 23.8% | — |
| EPS (diluted) | $0.23 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $391.6M | — | ||
| Q3 25 | $392.2M | $699.9M | ||
| Q2 25 | $366.2M | $613.9M | ||
| Q1 25 | $332.1M | $692.8M | ||
| Q4 24 | $339.3M | $707.8M | ||
| Q3 24 | $350.1M | $727.1M | ||
| Q2 24 | $319.8M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $10.2M | — | ||
| Q3 25 | $14.3M | $-733.0M | ||
| Q2 25 | $46.1M | $-255.4M | ||
| Q1 25 | $-4.4M | $-12.7M | ||
| Q4 24 | $8.2M | $-178.4M | ||
| Q3 24 | $13.7M | $-19.9M | ||
| Q2 24 | $8.0M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 31.5% | — | ||
| Q4 24 | 32.7% | — | ||
| Q3 24 | 33.7% | — | ||
| Q2 24 | 33.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.0% | -100.7% | ||
| Q2 25 | 2.6% | -29.4% | ||
| Q1 25 | 0.4% | 4.7% | ||
| Q4 24 | 3.5% | -14.2% | ||
| Q3 24 | 6.2% | 2.1% | ||
| Q2 24 | 1.2% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 3.6% | -104.7% | ||
| Q2 25 | 12.6% | -41.6% | ||
| Q1 25 | -1.3% | -1.8% | ||
| Q4 24 | 2.4% | -25.2% | ||
| Q3 24 | 3.9% | -2.7% | ||
| Q2 24 | 2.5% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $0.23 | — | ||
| Q3 25 | $0.31 | $-10.78 | ||
| Q2 25 | $0.99 | $-3.77 | ||
| Q1 25 | $-0.10 | $-0.19 | ||
| Q4 24 | $0.18 | $-2.54 | ||
| Q3 24 | $0.30 | $-0.30 | ||
| Q2 24 | $0.17 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $140.4M |
| Total DebtLower is stronger | $25.7M | $2.5B |
| Stockholders' EquityBook value | $1.9B | $1.9B |
| Total Assets | $2.4B | $5.6B |
| Debt / EquityLower = less leverage | 0.01× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $377.0M | — | ||
| Q3 25 | $386.4M | $98.1M | ||
| Q2 25 | $327.3M | $151.7M | ||
| Q1 25 | $343.9M | $127.1M | ||
| Q4 24 | $316.1M | $98.3M | ||
| Q3 24 | $319.3M | $143.7M | ||
| Q2 24 | $273.9M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $25.7M | — | ||
| Q3 25 | $24.9M | $2.5B | ||
| Q2 25 | $26.4M | $2.1B | ||
| Q1 25 | $20.5M | $2.1B | ||
| Q4 24 | $20.7M | $2.1B | ||
| Q3 24 | $22.2M | $2.2B | ||
| Q2 24 | $20.3M | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $2.0B | ||
| Q2 25 | $1.9B | $2.8B | ||
| Q1 25 | $1.8B | $3.0B | ||
| Q4 24 | $1.8B | $3.0B | ||
| Q3 24 | $1.8B | $3.2B | ||
| Q2 24 | $1.8B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $5.7B | ||
| Q2 25 | $2.5B | $6.4B | ||
| Q1 25 | $2.4B | $6.5B | ||
| Q4 24 | $2.4B | $6.4B | ||
| Q3 24 | $2.4B | $6.8B | ||
| Q2 24 | $2.4B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | 1.23× | ||
| Q2 25 | 0.01× | 0.74× | ||
| Q1 25 | 0.01× | 0.70× | ||
| Q4 24 | 0.01× | 0.72× | ||
| Q3 24 | 0.01× | 0.68× | ||
| Q2 24 | 0.01× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.1M | — |
| Free Cash FlowOCF − Capex | $12.4M | — |
| FCF MarginFCF / Revenue | 3.2% | — |
| Capex IntensityCapex / Revenue | 6.6% | — |
| Cash ConversionOCF / Net Profit | 3.74× | — |
| TTM Free Cash FlowTrailing 4 quarters | $137.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.1M | — | ||
| Q3 25 | $79.1M | $-45.5M | ||
| Q2 25 | $41.5M | $-46.8M | ||
| Q1 25 | $56.7M | $65.6M | ||
| Q4 24 | $81.8M | $63.7M | ||
| Q3 24 | $54.4M | $117.9M | ||
| Q2 24 | $14.4M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $12.4M | — | ||
| Q3 25 | $62.8M | $-94.7M | ||
| Q2 25 | $21.1M | $-84.3M | ||
| Q1 25 | $40.8M | $9.4M | ||
| Q4 24 | $62.1M | $16.5M | ||
| Q3 24 | $39.4M | $71.4M | ||
| Q2 24 | $-3.5M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 3.2% | — | ||
| Q3 25 | 16.0% | -13.5% | ||
| Q2 25 | 5.8% | -13.7% | ||
| Q1 25 | 12.3% | 1.4% | ||
| Q4 24 | 18.3% | 2.3% | ||
| Q3 24 | 11.2% | 9.8% | ||
| Q2 24 | -1.1% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.2% | 7.0% | ||
| Q2 25 | 5.6% | 6.1% | ||
| Q1 25 | 4.8% | 8.1% | ||
| Q4 24 | 5.8% | 6.7% | ||
| Q3 24 | 4.3% | 6.4% | ||
| Q2 24 | 5.6% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 3.74× | — | ||
| Q3 25 | 5.54× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 9.93× | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | 1.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
